In cases without MCI and both positive amyloid and tau neurofibrillary tangle biomarkers, we propose categorizing patients as demonstrating “epileptic preclinical AD,” corresponding with terminology proposed for biopathologic preclinical AD (56). The gene discussed is MAPT; the disease is Alzheimer disease.